[go: up one dir, main page]

NI201500100A - Mã‰todos de tratamiento de la deficiencia de hierro con pirofosfato fã‰rrico soluble - Google Patents

Mã‰todos de tratamiento de la deficiencia de hierro con pirofosfato fã‰rrico soluble

Info

Publication number
NI201500100A
NI201500100A NI201500100A NI201500100A NI201500100A NI 201500100 A NI201500100 A NI 201500100A NI 201500100 A NI201500100 A NI 201500100A NI 201500100 A NI201500100 A NI 201500100A NI 201500100 A NI201500100 A NI 201500100A
Authority
NI
Nicaragua
Prior art keywords
methods
iron deficiency
ferric pyrophosphate
soluble ferric
treatment
Prior art date
Application number
NI201500100A
Other languages
English (en)
Inventor
Gupta Ajay
Original Assignee
Charak Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50097899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201500100(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Charak Llc filed Critical Charak Llc
Publication of NI201500100A publication Critical patent/NI201500100A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)

Abstract

La invención proporciona métodos de tratamiento de la deficiencia de hierro y métodos para reducir o eliminar la dosis del agente estimulante de eritropoyesis para aumentar o mantener los niveles de hemoglobina en el rango objetivo en un sujeto que sufre de anemia, que comprende administrar pirofosfato férrico soluble en una cantidad eficaz para mantener o aumentar los niveles de hemoglobina en el sujeto.
NI201500100A 2013-02-01 2015-07-31 Mã‰todos de tratamiento de la deficiencia de hierro con pirofosfato fã‰rrico soluble NI201500100A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361759531P 2013-02-01 2013-02-01

Publications (1)

Publication Number Publication Date
NI201500100A true NI201500100A (es) 2019-05-07

Family

ID=50097899

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500100A NI201500100A (es) 2013-02-01 2015-07-31 Mã‰todos de tratamiento de la deficiencia de hierro con pirofosfato fã‰rrico soluble

Country Status (19)

Country Link
US (3) US20150366907A1 (es)
EP (2) EP2950806B1 (es)
JP (3) JP2016507527A (es)
KR (1) KR102236714B1 (es)
CN (2) CN107007624A (es)
AU (3) AU2014212127A1 (es)
BR (1) BR112015018549A8 (es)
CA (1) CA2900043A1 (es)
CL (1) CL2015002171A1 (es)
EA (1) EA032407B1 (es)
IL (1) IL240257A0 (es)
MX (1) MX370139B (es)
NI (1) NI201500100A (es)
PE (1) PE20151751A1 (es)
PH (1) PH12015501708A1 (es)
SG (1) SG11201506022VA (es)
TW (1) TW201517913A (es)
WO (1) WO2014121155A1 (es)
ZA (1) ZA201506364B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2941479T3 (es) 2012-06-15 2023-05-23 Symrise Ag Composiciones que comprenden agentes que promueven la biosíntesis de hialuronano
AU2014346996B9 (en) * 2013-11-05 2020-04-30 Rockwell Medical, Inc. Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients
US11517555B2 (en) 2015-09-04 2022-12-06 Rockwell Medical, Inc. Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
CN106581053A (zh) * 2015-10-20 2017-04-26 华仁药业股份有限公司 一种具有补铁功能的腹膜透析液
EP3842808A4 (en) * 2018-08-24 2022-05-18 National University Corporation Yokohama National University ADMINISTRATION MANAGEMENT APPARATUS, ADMINISTRATION MANAGEMENT METHOD AND PROGRAM
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
CA3167616A1 (en) * 2020-02-11 2021-08-19 Louis Michael SNYDER System for determining an underlying cause of anemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6779468B1 (en) * 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
WO1998029434A1 (en) 1996-12-31 1998-07-09 Ford Henry Health System Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
US6779648B2 (en) * 2000-07-13 2004-08-24 Psi Sales, Inc. 360 Degree rotatable lifter arm for log singulator
JP2005068055A (ja) * 2003-08-22 2005-03-17 Fujiyakuhin Co Ltd 無機元素含有水性コロイド分散液
US7857977B2 (en) * 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
CN102861336A (zh) * 2005-12-23 2013-01-09 阿贾伊·古普塔 含铁的肠胃外营养组合物
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
BR112013017169A2 (pt) * 2011-01-07 2016-10-04 Merrion Res Iii Ltd composições farmacêuticas de ferro para administração oral

Also Published As

Publication number Publication date
MX2015009968A (es) 2016-03-11
EP3789034A1 (en) 2021-03-10
AU2018278891B2 (en) 2020-09-10
CN104936609B (zh) 2017-04-12
US20180280432A1 (en) 2018-10-04
BR112015018549A8 (pt) 2018-01-30
BR112015018549A2 (pt) 2017-07-18
EA032407B1 (ru) 2019-05-31
CN104936609A (zh) 2015-09-23
MX370139B (es) 2019-12-03
WO2014121155A1 (en) 2014-08-07
TW201517913A (zh) 2015-05-16
KR102236714B1 (ko) 2021-04-06
SG11201506022VA (en) 2015-08-28
EP2950806B1 (en) 2020-07-15
JP2021169525A (ja) 2021-10-28
CL2015002171A1 (es) 2016-02-05
JP2016507527A (ja) 2016-03-10
CA2900043A1 (en) 2014-08-07
US20200276232A1 (en) 2020-09-03
EA201591424A1 (ru) 2015-12-30
AU2014212127A1 (en) 2015-08-20
NZ710691A (en) 2020-09-25
ZA201506364B (en) 2022-07-27
CN107007624A (zh) 2017-08-04
IL240257A0 (en) 2015-09-24
PH12015501708A1 (en) 2015-10-12
AU2020286223A1 (en) 2021-01-07
EP2950806A1 (en) 2015-12-09
KR20160004257A (ko) 2016-01-12
PE20151751A1 (es) 2015-12-03
JP2019151669A (ja) 2019-09-12
HK1215185A1 (zh) 2016-08-19
AU2018278891A1 (en) 2019-01-03
US20150366907A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
NI201500100A (es) Mã‰todos de tratamiento de la deficiencia de hierro con pirofosfato fã‰rrico soluble
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2017016868A (es) Composiciones y metods para inhibir actividad de arginasa.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
MX373231B (es) Agente anticancerigeno.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX2015014589A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2017016096A (es) Agente antihipertensivo.
MX380835B (es) Terapia de combinación pac-1.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2018002681A (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2018011110A (es) Agente inductor de inmunidad.